NeuroSense Therapeutics, Ltd. (NASDAQ: NRSN) is a clinical-stage biotechnology company, which is focused on the research and development of treatments for neurodegenerative diseases. Shares of the biotech company are skyrocketing 91% through early trading on Thursday, January 19, 2023. Over the past three months, NeuroSense Therapeutics has seen average daily volume of 26,450 shares. However, volume of 59.03 million shares or dollar volume of around $142.26 million, has already exchanged hands through early trading.
Shares of NeuroSense Therapeutics are soaring after the company released positive final results from its biomarker study on Alzheimer’s Disease. The biomarker study set out to evaluate the potential of the company’s combination platform therapy as a viable treatment for Alzheimer’s.
Preliminary results showed that the novel biomarker, TDP-43, was elevated in Alzheimer’s patients compared to the healthy control group. For the final portion of the study, the company expanded the study with a larger healthy control group to help validate results.
The TDP-43 biomarker has been found in up to 57% of Alzheimer’s cases and have shown to be cytotoxic in both in vitro and in vivo. Being that TDP-43 is known to colocalize with senile plaques and neurofibrillary issues, a direct interaction between TDP-43 and amyloid-B (AB) are seen as hallmark biomarkers for Alzheimer’s patients.
In a separate Phase 2a clinical trial biomarker study for a different neurodegenerative disease, NeuroSense Therapeutics’ platform combination therapy has shown statistically significant reduction of TDP-43. The platform combination therapy is now being evaluated in at Phase 2b double-blind clinical trial for ALS. The company says it plans to initiate a Phase 2 double-blind proof-of-concept study in Alzheimer’s patients during the first half of 2023.
Disclosure: No position. Spotlight Growth has no relationships with any of the companies mentioned in this article and did not receive payment in any form for its creation. This is an opinion article and is not meant to be financial advise. We are not broker-dealers or investment professionals. Please conduct your own due diligence. For more information on our disclosures, please visit: https://spotlightgrowth.com/disclosures/